The Chimeric antigen receptor- T Cell Therapy Market is anticipated to grow at a significantly healthy CAGR of 35% during the forecast period of 2023 to 2030. The increase is primarily due to an increase in cancer patients’ rate combined with increased awareness of the therapy. This report covers all the qualitative and quantitative aspects of the Car-T Cell Therapy Market and also covers key drivers, restraints, challenges, and opportunities that are impacting the growth opportunities of the market, and its future market trends.
Chemotherapy, surgery, and radiation therapy were the mainstays of cancer treatment for many years. CAR-T cell therapy, on the other hand, has recently been introduced as a tremendously supportive treatment for cancer patients. This treatment has been one of the most significant breakthroughs since the introduction of chemotherapy. Chimeric antigen receptor (CAR) T-cell therapy is a technique that involves genetically modifying immune cells known as T cells (a type of white blood cell) in the laboratory so that they can recognize and kill cancer cells. CAR T-cell therapy is often referred to as a type of cell-based gene therapy because it involves changing the genes within T cells to help them attack cancer. The success rate of CAR-T cell therapy varies depending on the type of cancer being treated by a healthcare professional.
The market has been segmented on the basis of Type of Targeted Antigens, Type of Approach, Therapeutic Areas, Products, End Users, and by Regions. On the basis of Approach, Autologous was valued over US $700 Million for the year 2019 and was anticipated to grow at a compound annual growth rate of 25% while CD19 dominated the market among targeted antigens with a lion’s share of over 70% and is expected to grow at a compound annual growth rate of 26%. On the basis of Therapeutic Areas, diffuse large B-cell lymphoma presides the market with over 56% share for the year 2019.
Excessive smoking, as well as the intake of alcohol, remain the key factor attributing to the increase in the global prevalence of cancer. Obesity is also one of the predominant factors leading to cancers. According to a 2018 fact sheet published by the World Health Organization (WHO), tobacco consumption caused 7 million deaths each year. Lung cancer is the leading cause of death worldwide, accounting for 37% of all deaths. As a result, the growing number of cancer patients is expected to increase demand for CAR T-cell therapy and fuel the market's growth during the forecast period.
Despite positive clinical trial results, there are three major obstacles faced by CAR-T Cell Therapy Market: high-end commercial model, unwanted immune responses and side effects, demand and supply of CAR-T Cell Therapy. In many countries only limited number of certified academic medical centers, provide CAR-T Cell Therapy requiring the patients to look for alternative destinations. With increasing number of cancer patients, supply has been in-elastic as compared to demand.
On the basis of Regional Segmentation, Chimeric antigen receptor- T Cell Therapy Market is segmented as follows: North America, Latin America, Europe, Asia Pacific, Middle East and Africa, and Rest of the World. North America dominated the global CAR-T Cell Therapy market in 2021, accounting for over 60 percent of the total market share. The region's dominance is attributed to favorable reimbursement policies, rising incidences of severe lymphoblastic leukemia, early availability of CAR-T cell Therapy products, and high per capita healthcare expenditure. Western Europe and Asia Pacific, followed by North America led the market. Asia Pacific and Western Europe are anticipated to be the fastest-growing regions in the CAR-T therapy market in the coming years, with and expected CAGRs of 85% and 33%, respectively during the forecast period.
Major players of CAR-T Cell Therapy Market are Gilead Sciences, Novartis AG, Pfizer, Bluebird Bio, Sorrento Therapeutics, Celgene Corporation (Juno Therapeutics), Mustang Bio, Celyad, Fate Therapeutics and Allogeneic Therapeutics. Market leaders are focusing on Research and Development activities and new product launches as key strategy to enhance their market share.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of CAR-T Cell Therapy market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Type of Targeted Antigens
| |
Type of Approach
| |
Therapeutic Areas
| |
Product
| |
End Users
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
